Cell-free fetal DNA (cfDNA) test, also called NIPT/NIPS, is a prenatal screening blood test.
What it measures: Small DNA fragments released mainly from the placenta into the pregnant person's blood. It does not directly sample fetal cells.
When: Usually from 10 weeks of pregnancy onward.
What it screens for: Most commonly:
Down syndrome, trisomy 21
Trisomy 18 (Edwards syndrome)
Trisomy 13 (Patau syndrome)
Some sex-chromosome differences, depending on the panel
Accuracy: It is the most accurate screening test for trisomies 21, 18, and 13, but it is not diagnostic. False-positive, false-negative, and "no-result" outcomes can occur. Tietz Textbook of Laboratory Medicine, p. 2758.
Does not reliably assess: All genetic diseases, birth defects, or neural-tube defects such as spina bifida. Ultrasound and the usual second-trimester screening remain important.
If high-risk/positive: Genetic counseling, a detailed ultrasound, and confirmation with CVS or amniocentesis should be offered before making decisions. ACOG guidance
If low-risk/negative: It greatly lowers the chance of the screened chromosome conditions but cannot completely exclude them.
If no-call/nonreportable: This can occur when the fetal fraction is low or for technical/biological reasons. It warrants discussion with the obstetric clinician because nonreportable results are associated with a higher chance of aneuploidy. ACOG guidance
ACOG states that cfDNA can be performed starting at 10 weeks and that a positive result should be confirmed with CVS or amniocentesis. ACOG patient information
Do you mean you want help understanding a specific cfDNA report? If so, share the result wording, gestational age, and whether it says low risk, high risk, or no-call, with personal details removed.
This is a shared conversation. Sign in to Orris to start your own chat.